Results 131 to 140 of about 65,940 (289)
ABSTRACT BorF is a short‐chain flavin reductase from a desert soil bacterium that uses NADH to reduce FAD to FADH2, which is used by the tryptophan‐6‐halogenase BorH to chlorinate tryptophan in the biosynthetic pathway of borregomycin A. The X‐ray crystal structure of BorF bound to FAD was solved to 2.37 Å by molecular replacement.
Zheng Ma +3 more
wiley +1 more source
Experimental workflow and main findings of the study. ABSTRACT Visceral pain is a major symptom of inflammatory bowel diseases (IBDs), requiring effective treatment strategies. Gut epithelium, beyond maintaining barrier integrity and microbiota homeostasis, modulates neurosensorial circuitries, influencing visceral sensitivity.
Francesco Margiotta +7 more
wiley +1 more source
Research Progress on Upper Airway Cough Syndrome
ABSTRACT Upper airway cough syndrome (UACS) has been identified as a significant contributor to chronic cough in various national guidelines. However, the complexity of its pathogenesis, the lack of clarity surrounding its diagnostic criteria, and its overlap with other etiologies of chronic cough present considerable challenges in both diagnosis and ...
Wan‐Ting Huang, Jia Chen
wiley +1 more source
History of TRP channels and lower urinary tract function and dysfunction
The history of TRP channels and bladder started in the 1980-ies with the studies of Maggi and collaborators, who created the basis for using capsaicin and other vanilloids in LUT disorders.
Karl-Erik Andersson
doaj +1 more source
Abstract Purpose To analyse pain sensation after phototherapeutic keratectomy (PTK) using chilled eye drops or drops at room temperature during the early postoperative period. Methods Our randomised controlled, parallel‐group study conducted in the Department of Ophthalmology, Goethe‐University, Frankfurt (Main), Germany, with blinded participants and ...
Carolin Marion Kolb‐Wetterau +7 more
wiley +1 more source
Psilocybin as a novel treatment for chronic pain
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade +7 more
wiley +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source

